Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Rhea-AI Summary

Castle Biosciences, Inc. (CSTL) announces its CFO, Frank Stokes, being selected as a Top 25 CFO of Houston for the second consecutive year. Stokes is recognized for his financial leadership and contribution to the company's growth.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Investing). The annual award recognizes the top-performing CFOs by region, selected for their skills in leading complex financial departments and their ability to drive growth and profitability as influential financial leaders in their communities.

“I am proud of Frank for earning a second placement among Houston’s Top 25 CFOs,” said Derek Maetzold, president and chief executive officer at Castle Biosciences. “In a city as dynamic and competitive as Houston, this recognition is a testament to Frank’s financial leadership in the growth and development of our company.”

Stokes has served as Castle’s chief financial officer since December 2017. Stokes holds a B.S. degree in business administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.

The comprehensive list of the Top 25 CFOs of Houston for 2024 can be viewed here.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

About TOP CFOs

TOP CFOs (formerly Finance & Investing) is a comprehensive source for research and information, business news, and corporate actions related to banking, finance, public and private markets, and other topics relevant to CFOs. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on finance and capital markets.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410056539/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com



Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

Who has been selected as a Top 25 CFO of Houston for the second year in a row?

Frank Stokes, the chief financial officer of Castle Biosciences, Inc. (CSTL).

What award has Frank Stokes received?

Frank Stokes has been selected as a Top 25 CFO of Houston by TOP CFOs for his financial leadership.

When did Frank Stokes become the CFO of Castle Biosciences?

Frank Stokes has been serving as Castle's chief financial officer since December 2017.

Where did Frank Stokes earn his degrees?

Frank Stokes holds a B.S. degree in business administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.

What is the significance of Frank Stokes being recognized as a Top 25 CFO of Houston?

Frank Stokes' recognition highlights his financial leadership and contribution to Castle Biosciences' growth in a competitive city like Houston.